Editing Abbott Laboratories (section)

== Finances ==

===Accounts===
For the fiscal year 2021, Abbott Laboratories reported earnings of US$7.071 billion, with an annual revenue of US$43.075 billion, which grew 24.5% on an organic basis versus the year prior. Abbott's year-end 2021 stock price was $140.74.<ref name="10-K 2021">{{cite web |url=https://www.sec.gov/ix?doc=/Archives/edgar/data/1800/000110465922025141/abt-20211231x10k.htm |title=US SEC: Form 10-K Abbott Laboratories |publisher=[[U.S. Securities and Exchange Commission]] |date=18 February 2022 |access-date=13 May 2022 |archive-date=20 April 2022 |archive-url=https://web.archive.org/web/20220420200250/https://www.sec.gov/ix?doc=/Archives/edgar/data/1800/000110465922025141/abt-20211231x10k.htm |url-status=live }}</ref><ref>{{Cite web|url=https://www.macrotrends.net/stocks/charts/ABT/abbott-laboratories/revenue|title=Abbott Laboratories Revenue 2006–2021 {{!}} ABT|website=macrotrends.net|access-date=1 November 2018|archive-date=2 November 2018|archive-url=https://web.archive.org/web/20181102014657/https://www.macrotrends.net/stocks/charts/ABT/abbott-laboratories/revenue|url-status=live}}</ref>
{| class="wikitable float-left" style="text-align: right;"
!Year
!Revenue<br />in mil. US$
!Net income<br />in mil. US$
!Total assets<br />in mil. US$
!Price per share<br />in US$
!Employees
|-
|2005
|22,338
|3,372
|29,141
|17.37
|
|-
|2006
|22,476
|1,717
|36,178
|17.46
|
|-
|2007
|25,914
|3,606
|39,714
|21.34
|
|-
|2008
|29,528
|4,881
|42,419
|21.89
|
|-
|2009
|30,765
| 5,746
|52,582
|19.51
|
|-
|2010
|35,167
| 4,626
|60,574
|20.75
|
|-
|2011
|21,407
|4,728
|60,277
|21.26
|
|-
|2012
|19,050
|5,963
|67,235
|26.57
|
|-
|2013
|19,657
|2,576
|42,953
|31.90
|69,000
|-
|2014
|20,247
|2,284
|41,207
|37.39
|77,000
|-
|2015
|20,405
| 4,423
|41,247
|43.16
|74,000
|-
|2016
|20,998
|1,400
|52,666
|38.65
|75,000
|-
|2017
|27,390
|477
|76,250
|47.50
|99,000
|-
|2018
|30,578
|2,368
|67,173
|69.50
|103,000
|-
|2019
|31,904
|3,687
|67,887
|86.86
|107,000
|-
|2020
|34,608
|4,495
|72,548
|109.49
|109,000
|-
|2021
|43,075
|7,071
|75,196
|140.74
|113,000
|}

===Taxation===
{{See also|Double Irish arrangement}}
On 19 March 2019, it was reported that Abbott was a long-term user of the [[Double Irish]] tax structure, a legal but controversial Irish taxation tool used by US multinationals to reduce US corporate taxes on non-U.S profits.<ref name="di"/> Abbott's Irish holding company, the Bermuda-resident Abbott Laboratories Vascular Enterprises (ALVE), employed no staff in 2017, but was responsible for distributing Abbot's products and licensing its technology worldwide.<ref name="di"/> Newly filed accounts showed that ALVE was incorporated in 2003 and had a pre-tax profit of €2 billion in 2016 and 2017 on revenues of €5.2 billion; no taxation was paid on these profits.<ref name="di"/> ALVE had never filed accounts in Ireland since 2003 as it was structured as an [[unlimited liability company]] (ULC); however, new EU accounts directives required ALVE to file Irish accounts in 2018.<ref name="di"/> These accounts listed ALVE's registered office as the address of Ireland's largest tax-law firm, [[Matheson (law firm)|Matheson]], who have been identified with Double Irish tax structures for Microsoft and Google.<ref name="di">{{cite news|url=https://www.thejournal.ie/abbott-ireland-tax-avoidance-4528308-Mar2019/|title=How the IDA's top client used Ireland to siphon billions offshore tax-free|newspaper=[[TheJournal.ie]]|author=Peter Bodkin|date=19 March 2019|access-date=19 March 2019|quote=Meanwhile, through a myriad of subsidiaries and system of inter-company charges involving a variation on the infamous so-called 'double Irish' structure, its local operations have also legally shaved their tax bills with the Exchequer despite pulling in huge sales.|archive-date=19 March 2019|archive-url=https://web.archive.org/web/20190319121457/https://www.thejournal.ie/abbott-ireland-tax-avoidance-4528308-Mar2019/|url-status=live}}</ref><ref name="wsj">{{cite news|url=https://www.wsj.com/articles/dublin-moves-to-block-controversial-tax-gambit-1381890312|title=Dublin Moves to Block Controversial Tax Gambit|quote=At least 125 major U.S. companies have registered several hundred subsidiaries or investment funds at 70 Sir John Rogerson's Quay, a seven–story building in Dublin's docklands, according to a review of government and corporate records by The Wall Street Journal.  The common thread is the building's primary resident: Matheson, an Irish law firm that specializes in ways companies can use Irish tax law.|newspaper=[[The Wall Street Journal]]|date=15 October 2013|access-date=19 March 2019|author1=Damian Paletta|author2=Kate Linebaugh|archive-date=16 June 2018|archive-url=https://web.archive.org/web/20180616203914/https://www.wsj.com/articles/dublin-moves-to-block-controversial-tax-gambit-1381890312|url-status=live}}</ref>

In September 2021, the ''[[Irish Times]]'' reported that Abbott was using the [[Single malt tax|Single Malt]] tax tool to shield profits on its [[COVID-19 testing#Nucleic acid tests|COVID-19 testing kits]].<ref name=abbotlabs>{{cite news | newspaper=[[The Irish Times]] | url=https://www.irishtimes.com/news/health/pharma-giant-abbott-using-irish-single-malt-scheme-to-avoid-tax-on-profits-1.4674126 | title=Pharma giant Abbott using Irish 'single-malt' scheme to avoid tax on profits | first1=Pat | last1=Leahy | date=15 September 2021 | accessdate=16 September 2021 | archive-date=15 September 2021 | archive-url=https://web.archive.org/web/20210915040424/https://www.irishtimes.com/news/health/pharma-giant-abbott-using-irish-single-malt-scheme-to-avoid-tax-on-profits-1.4674126 | url-status=live }}</ref><ref>{{cite news | newspaper=[[The Irish Times]] | first1=Cliff | last1=Taylor | date=15 September 2021 | accessdate=16 September 2021 | url=https://www.irishtimes.com/business/economy/how-abbott-labs-devised-its-formula-for-single-malt-taxation-1.4674058?mode=sample&auth-failed=1&pw-origin=https%3A%2F%2Fwww.irishtimes.com%2Fbusiness%2Feconomy%2Fhow-abbott-labs-devised-its-formula-for-single-malt-taxation-1.4674058 | title=How Abbott Labs devised its formula for 'single Malt' taxation | archive-date=15 September 2021 | archive-url=https://web.archive.org/web/20210915213227/https://www.irishtimes.com/business/economy/how-abbott-labs-devised-its-formula-for-single-malt-taxation-1.4674058?mode=sample&auth-failed=1&pw-origin=https%3A%2F%2Fwww.irishtimes.com%2Fbusiness%2Feconomy%2Fhow-abbott-labs-devised-its-formula-for-single-malt-taxation-1.4674058 | url-status=live }}</ref>